Vandemeulebroecke, Marc
Novartis (Switzerland)
2 papers on CoChatORCID 0000-0002-6407-3140
Most cited papers
- Verified
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut
Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis
Cited by 1,547
- Verified
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet
Hidradenitis Suppurativa and TreatmentsAutoimmune and Inflammatory Disorders
Cited by 343
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free